Physician profile
John C Brooks
NPI 1609886530
$5,141.64
in general payments reported to CMS, 2019-2025
39 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $274 · 2021: $508 · 2022: $333 · 2023: $287 · 2024: $1,275 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $656.87 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $456.66 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $408.36 | 2019-2025 | |
| Amarin Pharma, INC. | $342.34 | 2019-2021 | |
| Lilly USA, LLC | $270.82 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $264.10 | 2019-2024 | Qulipta |
| Novo Nordisk INC | $262.99 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $262.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $242.53 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $189.60 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $142.38 | 2019-2024 | Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $124.44 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.74 | 2019-2025 | Ofev, Jascayd |
| Shield Therapeutics INC | $120.26 | 2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.